ZY19489 + ferroquine

ZY19489 + ferroquine is an investigational fixed-dose oral combination therapy for malaria, currently in clinical development. ZY19489 is a fast-killing, blood-stage antimalarial compound with a low propensity to select for resistance and no stable resistance detected in vitro or clinical studies. Ferroquine (FQ, also known as SR97193) is a 4-aminoquinoline derivative and the first organometallic antimalarial drug candidate; it overcomes chloroquine resistance by inhibiting hemozoin formation and generating reactive oxygen species within the parasite's digestive vacuole. The combination aims to provide potent activity against *Plasmodium falciparum* malaria by pairing two agents with distinct mechanisms of action to prevent resistance and maximize efficacy[1][3][4][6].

Other names

FQSR97193 (for ferroquine)